Niagen Bioscience, Inc. (FRA:OCD1)
Germany
· Delayed Price · Currency is EUR 5.35
+0.10 (1.90%)
At close: Dec 4, 2025
Niagen Bioscience Revenue
Niagen Bioscience had revenue of $33.99M USD in the quarter ending September 30, 2025, with 32.86% growth. This brings the company's revenue in the last twelve months to $124.71M, up 36.04% year-over-year. In the year 2024, Niagen Bioscience had annual revenue of $99.60M with 19.18% growth.
Revenue (ttm)
$124.71M
Revenue Growth
+36.04%
P/S Ratio
4.18
Revenue / Employee
$1.20M
Employees
104
Market Cap
444.05M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 99.60M | 16.03M | 19.18% |
| Dec 31, 2023 | 83.57M | 11.52M | 15.99% |
| Dec 31, 2022 | 72.05M | 4.60M | 6.82% |
| Dec 31, 2021 | 67.45M | 8.19M | 13.82% |
| Dec 31, 2020 | 59.26M | 12.97M | 28.01% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 30, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Jan 2, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SAP SE | 36.49B |
| Siemens Aktiengesellschaft | 78.91B |
| Allianz SE | 105.02B |
| Deutsche Telekom AG | 121.02B |
| Siemens Energy AG | 39.08B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Rheinmetall AG | 11.00B |
| Deutsche Bank Aktiengesellschaft | 29.86B |